{"component": "clause", "props": {"groups": [{"size": 9, "snippet_links": [{"key": "milestone-payments", "type": "clause", "offset": [17, 35]}, {"key": "based-on", "type": "definition", "offset": [76, 84]}, {"key": "in-the-field", "type": "clause", "offset": [131, 143]}, {"key": "in-the-territory", "type": "clause", "offset": [145, 161]}, {"key": "section-93", "type": "clause", "offset": [200, 211]}, {"key": "with-respect-to", "type": "clause", "offset": [254, 269]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [288, 307]}, {"key": "active-pharmaceutical-ingredient", "type": "definition", "offset": [401, 433]}, {"key": "pay-to", "type": "definition", "offset": [454, 460]}, {"key": "the-product", "type": "definition", "offset": [592, 603]}, {"key": "payments-due-hereunder", "type": "clause", "offset": [683, 705]}, {"key": "provided-that", "type": "definition", "offset": [707, 720]}, {"key": "development-of-a", "type": "clause", "offset": [728, 744]}, {"key": "payments-made", "type": "clause", "offset": [781, 794]}, {"key": "abandoned-product", "type": "definition", "offset": [816, 833]}, {"key": "abandonment-of-the", "type": "clause", "offset": [957, 975]}, {"key": "other-product", "type": "definition", "offset": [976, 989]}, {"key": "clinical-trial", "type": "definition", "offset": [1046, 1060]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [1131, 1171]}, {"key": "in-this-agreement", "type": "definition", "offset": [1172, 1189]}, {"key": "pursuant-to-section", "type": "clause", "offset": [1212, 1231]}, {"key": "all-products", "type": "clause", "offset": [1293, 1305]}, {"key": "breach-by", "type": "clause", "offset": [1340, 1349]}, {"key": "milestone-events", "type": "clause", "offset": [1445, 1461]}, {"key": "notice-of-continuation", "type": "definition", "offset": [1533, 1555]}, {"key": "in-accordance-with", "type": "clause", "offset": [1556, 1574]}, {"key": "certain-confidential-information", "type": "clause", "offset": [1626, 1658]}, {"key": "contained-in", "type": "definition", "offset": [1659, 1671]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [1716, 1788]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [1789, 1805]}, {"key": "securities-exchange-act-of-1934", "type": "definition", "offset": [1819, 1850]}, {"key": "as-amended", "type": "definition", "offset": [1852, 1862]}], "snippet": "Facet shall make milestone payments (each a \u201cMilestone Payment\u201d) to Trubion based on the first achievement of each milestone event in the Field, in the Territory for each Product as set forth in this Section 9.3. No Milestone Payment shall be made twice with respect to the same Product. For the purposes of this Section 9.3, two Products are deemed the \u201csame Product\u201d if one Product contains, as its active pharmaceutical ingredient, [ * ]. Facet shall pay to Trubion the amounts set forth below, within [ * ] after the first achievement of the corresponding milestone event with respect to the Product. Each Milestone Payment is non-refundable and non-creditable against any other payments due hereunder, provided that if the Development of a Product is abandoned, any Milestone Payments made with respect to such abandoned Product may be credited against the corresponding Milestone Payments payable on a Product which achieves such milestones after the abandonment of the other Product. For the purposes of this Section 9.3, the \u201c[ * ]\u201d of a Clinical Trial shall occur upon [ * ], \u201c[ * ]\u201d and \u201c[ * ]\u201d shall be [ * ] or, [ * ]. Notwithstanding anything to the contrary in this Agreement, if Trubion is deemed pursuant to Section 14.2(b) to have exercised its Opt-Out Option with respect to all Products on account of an uncured material breach by Trubion, the amount of the milestone payments due pursuant to this Section 9.3 with respect to milestone events achieved by all Products after Facet has provided Trubion with written notice of continuation in accordance with Section 14.2(b) shall be reduced by [ * ]. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ] [ * ] $ [ * ]", "samples": [{"hash": "6iuIA2dbSQg", "uri": "/contracts/6iuIA2dbSQg#development-milestone-payments", "label": "Collaboration and License Agreement (Facet Biotech Corp)", "score": 21.0, "published": true}], "hash": "2f4613a29df37e428f7f878a7352f6ac", "id": 1}, {"size": 7, "snippet_links": [{"key": "partial-consideration", "type": "clause", "offset": [3, 24]}, {"key": "granted-to", "type": "definition", "offset": [53, 63]}, {"key": "days-after", "type": "definition", "offset": [91, 101]}, {"key": "section-52", "type": "clause", "offset": [188, 199]}, {"key": "with-respect-to", "type": "clause", "offset": [233, 248]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [299, 317]}, {"key": "notice-to", "type": "definition", "offset": [406, 415]}, {"key": "the-development", "type": "clause", "offset": [442, 457]}, {"key": "upon-receipt-of", "type": "definition", "offset": [484, 499]}, {"key": "notice-of", "type": "definition", "offset": [509, 518]}, {"key": "applicable-development", "type": "definition", "offset": [662, 684]}, {"key": "payment-to", "type": "clause", "offset": [732, 742]}, {"key": "days-of-receipt", "type": "clause", "offset": [936, 951]}, {"key": "development-milestone-events", "type": "definition", "offset": [1192, 1220]}, {"key": "new-indication", "type": "definition", "offset": [1281, 1295]}, {"key": "mono-product", "type": "definition", "offset": [1437, 1449]}, {"key": "combination-product", "type": "definition", "offset": [1453, 1472]}, {"key": "for-clarity", "type": "clause", "offset": [1525, 1536]}, {"key": "an-affiliate", "type": "clause", "offset": [1626, 1638]}, {"key": "no-payment", "type": "clause", "offset": [1661, 1671]}, {"key": "amounts-owed", "type": "clause", "offset": [1796, 1808]}, {"key": "the-foregoing", "type": "definition", "offset": [2271, 2284]}, {"key": "due-and-payable", "type": "definition", "offset": [2421, 2436]}, {"key": "first-product", "type": "definition", "offset": [2479, 2492]}, {"key": "ind-acceptance", "type": "definition", "offset": [3046, 3060]}, {"key": "this-agreement", "type": "clause", "offset": [3141, 3155]}, {"key": "no-development", "type": "clause", "offset": [3259, 3273]}], "snippet": "In partial consideration for the rights and licenses granted to Coya hereunder, within ten days after the first achievement of each milestone event in a given Indication set forth in this Section 5.2 (Development Milestone Payments) with respect to a Product (each, a \u201cDevelopment Milestone Event\u201d) by or on behalf of Coya or any of its Affiliates or Sublicensees, Coya shall provide ARScience Bio written notice to ARScience Bio identifying the Development Milestone Event achieved. Upon receipt of any such notice of first achievement of a Development Milestone Event by Coya or its Affiliates or Sublicensees, ARScience Bio will promptly invoice Coya for the applicable Development Milestone Event and Coya will make a milestone payment to ARScience Bio in the amount set forth in this Section 5.2 (Development Milestone Payments) corresponding to such Development Milestone Event (each, a \u201cDevelopment Milestone Payment\u201d) within 45 days of receipt of such invoice. On an Indication-by-Indication basis, each Development Milestone Payment shall be payable only upon the first achievement of the corresponding Development Milestone Event by a Product, in any given Indication for which the Development Milestone Events have not been previously achieved (each such Indication, a \u201cNew Indication\u201d). No amounts shall be due for subsequent or repeated achievements of such Development Milestone Event with respect to the same or different Mono Product or Combination Product, as applicable, in such Indication. Accordingly and for clarity, the Development Milestone Payment shall be paid only once, when first achieved by Coya, an Affiliate or a Sublicensee, but no payment shall be due if the same milestone is subsequently achieved by one of Coya, an Affiliate or a Sublicensee. For clarity, the amounts owed in Column (a) below shall be due for the first Combination Product to achieve the Development Milestone Events in a New Indication and the amounts owned in Column (c) below shall be due for the first Mono Product to achieve the Development Milestone Events in a New Indication. Any Combination Product or Mono Product to achieve the Development Milestone Events in a New Indication after the first achievement of the Development Milestone Events as described in the foregoing sentence will cause the amounts in Column (b) with respect to a Combination Product and Column (d) with respect to a Mono Product to be due and payable by Coya upon each such occurrence. If the first Product to achieve a Development Milestone Event in any Indication is a Combination Product, the amounts in Column (a) below shall be due and payable by Coya. If the next Product to achieve a Development Milestone Event in a New Indication is a Mono Product, the amounts in Column (c) below would be due and payable by Coya; provided, that if such next Product to achieve a Development Milestone Event in a New Indication is a Combination Product, the amounts in Column (b) would be due and payable by Coya. By way of example, if a Combination Product achieves IND Acceptance in ALS, and is the first Product to achieve a Development Milestone Event under this Agreement, [***] will be due and payable by Coya. If subsequently a Mono Product achieves IND Acceptance in ALS, no Development Milestone Payments will be due and payable by Coya under this Agreement. However, if subsequently any Combination Product achieves IND Acceptance in Alzheimer\u2019s disease, [***] would be due and payable by Coya.", "samples": [{"hash": "fUYBGJx8GcD", "uri": "/contracts/fUYBGJx8GcD#development-milestone-payments", "label": "License Agreement (Coya Therapeutics, Inc.)", "score": 33.9253921509, "published": true}, {"hash": "aM5Ikwy4mnt", "uri": "/contracts/aM5Ikwy4mnt#development-milestone-payments", "label": "License Agreement (Coya Therapeutics, Inc.)", "score": 33.8788490295, "published": true}, {"hash": "d1E4VzUGvoo", "uri": "/contracts/d1E4VzUGvoo#development-milestone-payments", "label": "Licensing Agreement", "score": 27.8199863434, "published": true}], "hash": "61a1da67d3f83fc60886741d2c5563cd", "id": 2}, {"size": 4, "snippet_links": [{"key": "pay-to", "type": "definition", "offset": [12, 18]}, {"key": "the-development", "type": "clause", "offset": [29, 44]}, {"key": "listed-below", "type": "clause", "offset": [64, 76]}, {"key": "within-thirty", "type": "clause", "offset": [93, 106]}, {"key": "date-of", "type": "clause", "offset": [139, 146]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [190, 214]}, {"key": "pursuant-to-article", "type": "clause", "offset": [215, 234]}, {"key": "the-relevant", "type": "clause", "offset": [245, 257]}, {"key": "milestone-event", "type": "definition", "offset": [258, 273]}, {"key": "first-occurrence", "type": "definition", "offset": [566, 582]}], "snippet": "Lilly shall pay to \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 the Development milestone payments listed below as follows: (i) within thirty (30) days of the earlier of the date of FTO Submission and Lilly\u2019s election not to terminate this Agreement pursuant to Article 7.1(c) if the relevant milestone event occurs before such earliest date; or (ii) within thirty (30) days of the milestone event if the relevant milestone event occurs after the date of FTO Submission or Lilly\u2019s election not to terminate this Agreement pursuant to Article 7.1(c). Each milestone shall be payable only once upon the first occurrence of the described event for any Product.", "samples": [{"hash": "2ez19I7ilry", "uri": "/contracts/2ez19I7ilry#development-milestone-payments", "label": "Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.4072551727, "published": true}, {"hash": "fIgWtHiCQWi", "uri": "/contracts/fIgWtHiCQWi#development-milestone-payments", "label": "Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.3305950165, "published": true}, {"hash": "8GHkMDa8zmD", "uri": "/contracts/8GHkMDa8zmD#development-milestone-payments", "label": "Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.3305950165, "published": true}], "hash": "dc48b27c0c82325a75334eb77d664b10", "id": 9}, {"size": 4, "snippet_links": [{"key": "additional-consideration", "type": "definition", "offset": [3, 27]}, {"key": "granted-to", "type": "definition", "offset": [43, 53]}, {"key": "the-milestones", "type": "clause", "offset": [115, 129]}, {"key": "applicable-milestone-payment", "type": "definition", "offset": [176, 204]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [280, 306]}, {"key": "time-only", "type": "clause", "offset": [364, 373]}, {"key": "first-occurrence", "type": "definition", "offset": [383, 399]}, {"key": "the-event", "type": "definition", "offset": [403, 412]}], "snippet": "As additional consideration for the rights granted to Indivior herein, after the achievement by Indivior of any of the milestones set forth below, Indivior shall pay Addex the applicable milestone payment set forth next to such milestone below (\u201cDevelopment Milestone Payments\u201d). For the avoidance of doubt, each Development Milestone Payment shall be payable one-time only upon the first occurrence of the event triggering the respective milestone set forth in the table below.\n1. [***] [***]\n2. [***] [***]\n3. [***] [***]\n4. [***] [***]\n5. [***] [***]\n6. [***] [***]\n7. [***] [***]\n8. [***] [***]\n9. [***] [***]\n10. [***] [***] Total [***]", "samples": [{"hash": "1mqWkV876Xe", "uri": "/contracts/1mqWkV876Xe#development-milestone-payments", "label": "License Agreement (Indivior PLC)", "score": 32.388092041, "published": true}, {"hash": "d4wj7lDwfls", "uri": "/contracts/d4wj7lDwfls#development-milestone-payments", "label": "License Agreement (Indivior PLC)", "score": 32.1854896545, "published": true}, {"hash": "3h9UZnRUFDy", "uri": "/contracts/3h9UZnRUFDy#development-milestone-payments", "label": "License Agreement (Addex Therapeutics Ltd.)", "score": 30.9575634003, "published": true}], "hash": "0c672a87627665388d82d89c0648a8d2", "id": 10}, {"size": 5, "snippet_links": [{"key": "following-the", "type": "definition", "offset": [12, 25]}, {"key": "relevant-events", "type": "clause", "offset": [44, 59]}, {"key": "with-respect-to", "type": "clause", "offset": [76, 91]}, {"key": "licensee-shall", "type": "clause", "offset": [110, 124]}, {"key": "to-kosan", "type": "clause", "offset": [129, 137]}, {"key": "development-milestone-payment", "type": "definition", "offset": [161, 190]}], "snippet": "Within [**] following the occurrence of the relevant events specified below with respect to the each PRODUCT, LICENSEE shall pay to KOSAN the following amounts: DEVELOPMENT MILESTONE PAYMENT --------------------- ------- [**] $[**]", "samples": [{"hash": "jygzkJpU4Hl", "uri": "/contracts/jygzkJpU4Hl#development-milestone-payments", "label": "Research and License Agreement (Kosan Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "iYCKDMsqOUs", "uri": "/contracts/iYCKDMsqOUs#development-milestone-payments", "label": "Research and License Agreement (Kosan Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "iIfKFyUZgJf", "uri": "/contracts/iIfKFyUZgJf#development-milestone-payments", "label": "Research and License Agreement (Kosan Biosciences Inc)", "score": 18.0, "published": true}], "hash": "5a053edfb527cfab0866b5ec1ac8a9c7", "id": 5}, {"size": 5, "snippet_links": [{"key": "in-the-event", "type": "clause", "offset": [0, 12]}, {"key": "the-company", "type": "clause", "offset": [18, 29]}, {"key": "commercial-sale", "type": "definition", "offset": [115, 130]}, {"key": "in-the-territory", "type": "clause", "offset": [131, 147]}, {"key": "payments-shall-be", "type": "clause", "offset": [223, 240]}, {"key": "by-company", "type": "clause", "offset": [246, 256]}, {"key": "with-respect-to", "type": "clause", "offset": [269, 284]}, {"key": "first-product", "type": "definition", "offset": [289, 302]}, {"key": "first-indication", "type": "clause", "offset": [442, 458]}], "snippet": "In the event that the Company, Sublicensees, or their Affiliates (collectively \u201cDeveloper\u201d) develops a Product for commercial sale in the Territory, the following nonrefundable, non-recoverable and non-creditable milestone payments shall be made by Company to Columbia with respect to the first Product as follows: [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] The above milestone payment shall be paid on the first Product and first indication only.", "samples": [{"hash": "hqMSEY3LoiU", "uri": "/contracts/hqMSEY3LoiU#development-milestone-payments", "label": "Exclusive License Agreement (Belite Bio, Inc)", "score": 33.257358551, "published": true}, {"hash": "eK0DJkr7nK1", "uri": "/contracts/eK0DJkr7nK1#development-milestone-payments", "label": "Exclusive License Agreement (Belite Bio, Inc)", "score": 33.0547561646, "published": true}], "hash": "189e08cfd198f84a498280dbace13d21", "id": 6}, {"size": 4, "snippet_links": [{"key": "licensed-products", "type": "clause", "offset": [67, 84]}, {"key": "the-licensee-shall", "type": "clause", "offset": [85, 103]}, {"key": "milestone-event", "type": "definition", "offset": [263, 278]}, {"key": "the-relevant", "type": "clause", "offset": [333, 345]}, {"key": "development-milestone-payment", "type": "definition", "offset": [346, 375]}, {"key": "upon-occurrence-of-the", "type": "clause", "offset": [391, 413]}], "snippet": "Upon achievement of the following milestones events for any of the Licensed Products the Licensee shall pay NTUitive the following non-refundable sums.\n(a) [\u2026***\u2026]\n(b) [\u2026***\u2026]\n(c) [\u2026***\u2026]\n(d) [\u2026***\u2026] The Licensee shall notify NTUitive upon the occurrence of each milestone event above within [\u2026***\u2026] of such occurrence and shall pay the relevant Development Milestone Payment within [\u2026***\u2026] upon occurrence of the milestone.", "samples": [{"hash": "lsQzVIOTjZS", "uri": "/contracts/lsQzVIOTjZS#development-milestone-payments", "label": "Licensing and Research Collaboration Agreement", "score": 29.3408622742, "published": true}, {"hash": "cKu0ANdembq", "uri": "/contracts/cKu0ANdembq#development-milestone-payments", "label": "Licensing and Research Collaboration Agreement (ASLAN Pharmaceuticals LTD)", "score": 27.2299785614, "published": true}, {"hash": "dU4kW7kQ9XW", "uri": "/contracts/dU4kW7kQ9XW#development-milestone-payments", "label": "Licensing and Research Collaboration Agreement (ASLAN Pharmaceuticals LTD)", "score": 27.1560573578, "published": true}], "hash": "0b9242464138fa6408f7be3c9afcfd77", "id": 8}, {"size": 6, "snippet_links": [{"key": "payments-to", "type": "clause", "offset": [39, 50]}, {"key": "milestone-events", "type": "clause", "offset": [115, 131]}, {"key": "with-respect-to", "type": "clause", "offset": [143, 158]}, {"key": "respective-affiliates", "type": "definition", "offset": [200, 221]}, {"key": "transfer-of", "type": "definition", "offset": [289, 300]}, {"key": "immediately-available-funds", "type": "clause", "offset": [301, 328]}, {"key": "by-sgi", "type": "clause", "offset": [356, 362]}, {"key": "payable-to", "type": "definition", "offset": [477, 487]}, {"key": "the-designated", "type": "clause", "offset": [517, 531]}, {"key": "information-on", "type": "clause", "offset": [832, 846]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [866, 938]}, {"key": "confidential-treatment", "type": "clause", "offset": [940, 962]}, {"key": "first-licensed-product", "type": "definition", "offset": [1112, 1134]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [1399, 1428]}, {"key": "in-the-event", "type": "clause", "offset": [1475, 1487]}, {"key": "in-good-faith", "type": "definition", "offset": [1519, 1532]}, {"key": "the-relevant", "type": "clause", "offset": [1636, 1648]}], "snippet": "MPI shall make the following milestone payments to SGI within [***] after the achievement of each of the following milestone events by MPI or, with respect to the [***], SGI, or, as applicable, their respective Affiliates or sublicensees. Each such milestone payment shall be made by wire transfer of immediately available funds into an account designated by SGI. Each such milestone payment shall be [***].\n(a) [***]. The milestone payments listed in the table below shall be payable to SGI for the [***] to achieve the designated milestone event with respect to [***]. [***] [***] [***] [***] [***] [***] [***] [***]\n(b) [***]. The milestone payments listed in the table below shall be payable to SGI for the [***] to achieve the designated milestone event with respect to [***]. [***] [***] [***] [***] [***] [***] [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.\n(c) [***]. The milestone payments listed in the table below shall be payable to SGI for the first Licensed Product to achieve the designated milestone event with respect to [***]. [***] [***] [***] [***] [***] [***]\n(d) [***]. The milestone payments listed in the table below shall be payable to SGI for the [***] to achieve the designated milestone event with respect to [***]. Notwithstanding the foregoing, with respect to each such milestone payment, in the event that MPI reasonably determines in good faith, and shares its determination with SGI at least [***] before the reasonably anticipated achievement of the relevant milestone event, [***]. If SGI disputes such [***]. If SGI does not provide such notice and [***]. [***] [***] [***] [***] [***] [***] [***] [***]\n(e) [***]. The milestone payments listed in the table below shall be payable to SGI for the [***] to achieve the designated milestone event with respect to the [***]. Notwithstanding the foregoing, with respect to each such milestone payment, in the event that [***]. If SGI disputes such [***]. If SGI does not provide such notice and [***]. [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]", "samples": [{"hash": "fhw7KqRCOuT", "uri": "/contracts/fhw7KqRCOuT#development-milestone-payments", "label": "Collaboration Agreement (Takeda Pharmaceutical Co LTD)", "score": 29.873374939, "published": true}], "hash": "3940dd5d1a023c65c35dc708e93b3e8b", "id": 4}, {"size": 6, "snippet_links": [{"key": "payments-to", "type": "clause", "offset": [88, 99]}, {"key": "days-after", "type": "definition", "offset": [118, 128]}, {"key": "with-respect-to", "type": "clause", "offset": [186, 201]}, {"key": "during-the-term", "type": "clause", "offset": [309, 324]}, {"key": "first-time", "type": "definition", "offset": [330, 340]}, {"key": "number-of", "type": "clause", "offset": [402, 411]}, {"key": "subsequent-products", "type": "clause", "offset": [485, 504]}, {"key": "for-clarification", "type": "clause", "offset": [536, 553]}, {"key": "the-total", "type": "clause", "offset": [555, 564]}, {"key": "milestone-events", "type": "clause", "offset": [609, 625]}], "snippet": "Artiva shall make the following non-refundable and non-creditable development milestone payments to GCLC within [***] days after the first achievement of each applicable milestone event with respect to a Product by Artiva or its Affiliates or Sublicensees. Each such milestone payment shall be paid only once during the Term, the first time a Product reaches such milestone event and regardless of the number of times such milestone event is reached for a Product and of the number of subsequent Products reaching such milestone event. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].", "samples": [{"hash": "hK5PsbkjOpv", "uri": "/contracts/hK5PsbkjOpv#development-milestone-payments", "label": "Selected Product License Agreement (Artiva Biotherapeutics, Inc.)", "score": 35.4887046814, "published": true}, {"hash": "kj8KndXIG4I", "uri": "/contracts/kj8KndXIG4I#development-milestone-payments", "label": "Selected Product License Agreement (Artiva Biotherapeutics, Inc.)", "score": 35.3353881836, "published": true}, {"hash": "lJgiOoJnZUx", "uri": "/contracts/lJgiOoJnZUx#development-milestone-payments", "label": "Selected Product License Agreement (Artiva Biotherapeutics, Inc.)", "score": 32.266254425, "published": true}], "hash": "27a382bbfcc625f4cf949f948eb59134", "id": 3}, {"size": 4, "snippet_links": [{"key": "payments-to", "type": "clause", "offset": [88, 99]}, {"key": "days-after", "type": "definition", "offset": [118, 128]}, {"key": "with-respect-to", "type": "clause", "offset": [186, 201]}, {"key": "during-the-term", "type": "clause", "offset": [309, 324]}, {"key": "first-time", "type": "definition", "offset": [330, 340]}, {"key": "number-of", "type": "clause", "offset": [402, 411]}, {"key": "subsequent-products", "type": "clause", "offset": [485, 504]}, {"key": "for-clarification", "type": "clause", "offset": [536, 553]}, {"key": "the-total", "type": "clause", "offset": [555, 564]}, {"key": "milestone-events", "type": "clause", "offset": [609, 625]}], "snippet": "Artiva shall make the following non-refundable and non-creditable development milestone payments to GCLC within [***] days after the first achievement of each applicable milestone event with respect to a Product by Artiva or its Affiliates or Sublicensees. Each such milestone payment shall be paid only once during the Term, the first time a Product reaches such milestone event and regardless of the number of times such milestone event is reached for a Product and of the number of subsequent Products reaching such milestone event. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***]. 1 [***] [***] 2 [***] [***] 3 [***] [***] 4 [***] [***] 5 [***] [***] 6 [***] [***] 7 [***] [***] 8 [***] [***] 9 [***] [***] 10 [***] [***] 11 [***] [***] 12 [***] [***]", "samples": [{"hash": "8yLIcZK8Wyt", "uri": "/contracts/8yLIcZK8Wyt#development-milestone-payments", "label": "Selected Product License Agreement (Artiva Biotherapeutics, Inc.)", "score": 35.4887046814, "published": true}, {"hash": "legTSXEYhpr", "uri": "/contracts/legTSXEYhpr#development-milestone-payments", "label": "Selected Product License Agreement (Artiva Biotherapeutics, Inc.)", "score": 35.3353881836, "published": true}, {"hash": "3TyeEKDOAYF", "uri": "/contracts/3TyeEKDOAYF#development-milestone-payments", "label": "Selected Product License Agreement (Artiva Biotherapeutics, Inc.)", "score": 32.266254425, "published": true}], "hash": "97750ad1d408bb77442da2542a4e3423", "id": 7}], "next_curs": "CmcSYWoVc35sYXdpbnNpZGVyY29udHJhY3RzckMLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IidkZXZlbG9wbWVudC1taWxlc3RvbmUtcGF5bWVudHMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"size": 615, "parents": [["payments", "Payments"], ["compensation", "Compensation"], ["financial-provisions", "Financial Provisions"], ["milestone-payments", "Milestone Payments"], ["financial-terms", "Financial Terms"]], "title": "Development Milestone Payments", "children": [["notice-and-payment", "Notice and Payment"], ["", ""], ["development-milestones", "Development Milestones"], ["development-milestone-payments", "Development Milestone Payments"], ["notice-payment", "Notice; Payment"]], "id": "development-milestone-payments", "related": [["development-milestones", "Development Milestones", "Development Milestones"], ["sales-milestone-payments", "Sales Milestone Payments", "Sales Milestone Payments"], ["milestone-event-milestone-payment", "Milestone Event Milestone Payment", "Milestone Event Milestone Payment"], ["milestone-payment", "Milestone Payment", "Milestone Payment"], ["milestone-payments", "Milestone Payments", "Milestone Payments"]], "related_snippets": [], "updated": "2026-06-24T06:10:05+00:00"}, "json": true, "cursor": ""}}